Prognostic value of estrogen receptors in patients who underwent prostatectomy for non‑metastatic prostate cancer

Aydın,Yavuz Mert; Şahin,Ahmet Bilgehan; Dölek,Rabia; Vuruşkan,Berna Aytaç; Ocakoğlu,Gökhan; Vuruşkan,Hakan; Yavaşcaoğlu,İsmet; Coşkun,Burhan

doi:10.3892/ol.2023.13664

Prognostic value of estrogen receptors in patients who underwent prostatectomy for non‑metastatic prostate cancer

Authors:
- Yavuz Mert Aydın
- Ahmet Bilgehan Şahin
- Rabia Dölek
- Berna Aytaç Vuruşkan
- Gökhan Ocakoğlu
- Hakan Vuruşkan
- İsmet Yavaşcaoğlu
- Burhan Coşkun
View Affiliations

Affiliations: Department of Urology, Bursa Uludag University, 16059 Bursa, Turkey, Department of Medical Oncology, Bursa Uludag University, 16059 Bursa, Turkey, Department of Pathology, Bursa Uludag University, 16059 Bursa, Turkey, Department of Biostatistics, Bursa Uludag University, 16059 Bursa, Turkey
Published online on: January 9, 2023 https://doi.org/10.3892/ol.2023.13664
Article Number: 78

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Estrogen receptors in prostate cancer (PCa) are a subject of debate. The aim of the present study was to investigate whether estrogen receptor‑α (ERα) and estrogen receptor‑β (ERβ) impact the biochemical recurrence (BCR) of non‑metastatic PCa after surgery. Following the application of the exclusion criteria, data from 108 patients who underwent laparoscopic radical prostatectomy between January 2011 and December 2019 were retrospectively evaluated. A total of 36 patients with BCR constituted the BCR group. The control group was formed using the Propensity Score Matching (PSM) method with a 1:2 ratio, including parameters with well‑studied effects on BCR. The median follow‑up time was 74.3 (range, 30‑127.5) months in the BCR group and 66.6 (range, 31.5‑130) months in the control group. Pathology specimens from the two groups were immunohistochemically stained with ERα and ERβ antibodies. Logistic regression analysis and survival analysis were performed. No differences in clinicopathological characteristics were detected between the two groups. The patients with ERα(‑)/ERβ(+) staining results had a significantly fewer BCRs than other patients (P=0.024). In the logistic regression analysis, patients with ERα(‑)/ERβ(+) PCa also had a significantly lower risk of recurrence (P=0.048). In the survival analysis, the 5‑year BCR‑free survival rate of patients with ERα(‑)/ERβ(+) PCa was higher than that of other patients (85.7 vs. 66.1%; P=0.031). Excluding the effects of well‑studied risk factors for recurrence by the PSM method, the present study showed that ERα and ERβ have prognostic value for non‑metastatic PCa. The 5‑year BCR‑free survival rate is significantly higher in patients whose PCa tissue has ERα(‑)/ERβ(+) staining results.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of ıncidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ and Timms B: Human prostate cancer risk factors. Cancer. 101 (10 Suppl):S2371–S2490. 2004. View Article : Google Scholar : PubMed/NCBI
3	Dobbs RW, Malhotra NR, Greenwald DT, Wang AY, Prins GS and Abern MR: Estrogens and prostate cancer. Prostate Cancer Prostatic Dis. 22:185–194. 2019. View Article : Google Scholar : PubMed/NCBI
4	Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, et al: Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 100:815–825. 2008. View Article : Google Scholar : PubMed/NCBI
5	McPherson SJ, Hussain S, Balanathan P, Hedwards SL, Niranjan B, Grant M, Chandrasiri UP, Toivanen R, Wang Y, Taylor RA and Risbridger GP: Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci USA. 107:3123–3128. 2010. View Article : Google Scholar : PubMed/NCBI
6	Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, Gouvin LM, Sharma VM and Mercurio AM: ERβ ımpedes prostate cancer EMT by destabilizing HIF-1α and inhibiting VEGF-mediated snail nuclear localization: Implications for gleason grading. Cancer Cell. 17:319–332. 2010. View Article : Google Scholar : PubMed/NCBI
7	Risbridger G, Wang H, Young P, Kurita T, Wang YZ, Lubahn D, Gustafsson JA and Cunha G: Evidence that epithelial and mesenchymal estrogen receptor-α mediates effects of estrogen on prostatic epithelium. Dev Biol. 229:432–442. 2001. View Article : Google Scholar : PubMed/NCBI
8	Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B and Korach KS: Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: Studies with alphaERKO and betaERKO mice. Cancer Res. 61:6089–6097. 2001.PubMed/NCBI
9	Bonkhoff H, Fixemer T, Hunsicker I and Remberger K: Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol. 155:641–647. 1999. View Article : Google Scholar : PubMed/NCBI
10	Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE and Ho SM: Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol. 164:2003–2012. 2004. View Article : Google Scholar : PubMed/NCBI
11	Zhang X, Leung YK and Ho SM: AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells. Oncogene. 26:7346–7354. 2007. View Article : Google Scholar : PubMed/NCBI
12	Cheng J, Lee EJ, Madison LD and Lazennec G: Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett. 566:169–172. 2004. View Article : Google Scholar : PubMed/NCBI
13	Weihua Z, Warner M and Gustafsson JA: Estrogen receptor beta in the prostate. Mol Cell Endocrinol. 193:1–5. 2002. View Article : Google Scholar : PubMed/NCBI
14	McPherson SJ, Ellem SJ, Simpson ER, Patchev V, Fritzemeier KH and Risbridger GP: Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology. 148:566–574. 2007. View Article : Google Scholar : PubMed/NCBI
15	Megas G, Chrisofos M, Anastasiou I, Tsitlidou A, Choreftaki T and Deliveliotis C: Estrogen receptor (α and β) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population. Asian J Androl. 17:98–105. 2015. View Article : Google Scholar : PubMed/NCBI
16	Grindstad T, Skjefstad K, Andersen S, Ness N, Nordby Y, Al-Saad S, Fismen S, Donnem T, Khanehkenari MR, Busund LT, et al: Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome. Sci Rep. 6:331142016. View Article : Google Scholar : PubMed/NCBI
17	Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G, et al: Frequent loss of estrogen receptor-β expression in prostate cancer. Cancer Res. 61:5331–5335. 2001.PubMed/NCBI
18	Nelson JB and Lepor H: Prostate cancer: Radical prostatectomy. Urol Clin North Am. 30:703–723. 2003. View Article : Google Scholar : PubMed/NCBI
19	Bonkhoff H: Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression. Prostate. 78:2–10. 2018. View Article : Google Scholar : PubMed/NCBI
20	Qu LG, Wardan H, Davis ID, Pezaro C and Sluka P: Effects of estrogen receptor signaling on prostate cancer carcinogenesis. Transl Res. 222:56–66. 2020. View Article : Google Scholar : PubMed/NCBI
21	He Y, Xu W, Xiao YT, Huang H, Gu D and Ren S: Targeting signaling pathways in prostate cancer: Mechanisms and clinical trials. Signal Transduct Target Ther. 7:1982022. View Article : Google Scholar : PubMed/NCBI
22	Mottet N, Vice-Chair PC, Bergh RCN, Van Den, Mottet N, et al: Guidelines on Prostate Cancer. Update. 53:31–45. 2021.
23	Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, et al: Two positive nodes represent a significant Cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a Two-ınstitution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol. 55:261–270. 2009. View Article : Google Scholar : PubMed/NCBI
24	Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, et al: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and ımproves survival: Long-term followup of a randomized clinical trial. J Urol. 181:956–962. 2009. View Article : Google Scholar : PubMed/NCBI
25	Bolla M, Van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, et al: Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 380:2018–2027. 2012. View Article : Google Scholar : PubMed/NCBI
26	Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, et al: Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 66:243–250. 2014. View Article : Google Scholar : PubMed/NCBI
27	Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, Luukkaala T, Salonen A, Isotalo T, Pétas A, et al: Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension. Eur Urol. 76:586–595. 2019. View Article : Google Scholar : PubMed/NCBI
28	Shapiro E, Huang H, Masch RJ, McFadden DE, Wilson EL and Wu XR: Immunolocalization of estrogen receptor α and β in human fetal prostate. J Urol. 174:2051–2053. 2005. View Article : Google Scholar : PubMed/NCBI
29	Prins GS and Korach KS: The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 73:233–244. 2008. View Article : Google Scholar : PubMed/NCBI
30	Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Marketon JW, Jensen EV, Nilsson S, Warner M and Gustafsson JA: A role for estrogen receptor? in the regulation of the ventral prostate. Proce National Acad Sci. 98:6330–6335. 2001. View Article : Google Scholar : PubMed/NCBI
31	Terlizzi M, Limkin EJ, Moukasse Y and Blanchard P: Adjuvant or salvage radiation therapy for prostate cancer after prostatectomy: Current status, controversies and perspectives. Cancers (Basel). 14:16882022. View Article : Google Scholar : PubMed/NCBI